CompletedPhase 2NCT00887107

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

Studying Medullary thyroid carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Leiden University Medical Center
Principal Investigator
Johannes W Smit, MD, PhD
Leiden Universty Medical Center
Intervention
Sorafenib (nexavar)(drug)
Enrollment
32 enrolled
Eligibility
18-80 years · All sexes
Timeline
2007

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00887107 on ClinicalTrials.gov

Other trials for Medullary thyroid carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Medullary thyroid carcinoma →

← Back to all trials